Skip to content

Gilead Sciences GILD Return on equity

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
38.8%+7.3pp
Incyte logo
IncyteINCY
30.8%+30.4pp
Merck & Co. logo
Merck & Co.MRK
19%-20.3pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
26.4%-3.0pp
ALN
Alnylam PharmaceuticalsALNY
66.9%
Biogen logo
BiogenBIIB
8%-1.2pp

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$155.75B+23.8%
Enterprise value$170.3B+19.7%
P/E16.9×-4.2×
P/S5.2×+0.9×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp

Returns & leverage

See full
Debt / equity0.9×-0.4×
Current ratio+0.6×

Where this comes from

Calculated from Gilead Sciences’s reported figures.

Based on trailing twelve months.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's return on equity?
Gilead Sciences (GILD) reported return on equity of 43.2% in Q1 2026.
How has Gilead Sciences's return on equity changed year-over-year?
Gilead Sciences's return on equity increased by 32.9% year-over-year, from 32.5% to 43.2%.
What is the long-term trend for Gilead Sciences's return on equity?
Over 4 years (2021 to 2025), Gilead Sciences's return on equity has grown at a 10.5% compound annual growth rate (CAGR), from 98.5% to 146.8%.
What does return on equity mean?
How much profit the company earns on the money shareholders have invested.
How do you interpret return on equity?
Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
How does return on equity compare across companies?
Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.